Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor
Naporafenib是一種潛在的首創和最佳的全RAF抑制劑
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses
Erasca還在進行中的SEACRAFt-2關鍵3期試驗中評估了naporafenib和trametinib的聯合應用，在此前的NRAS突變黑色素瘤合併分析中已經顯示出有利的生存
Erasca to host virtual R&D update for investors on Thursday, October 24, 2024, at 8:30 AM ET
Erasca將於2024年10月24日星期四美國東部時間上午8:30舉行虛擬投資者研發更新會議
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.
聖地亞哥，2024年9月25日（環球社會新聞通訊社）-- Erasca公司（納斯達克：ERAS），一家專注於發現、開發和商業化RAS/MAPk通路驅動癌症患者的療法的臨床階段精準腫瘤學公司，今天宣佈了在第36屆EORTC-NCI-AACR（ENA）分子靶向與癌症治療研討會上展示naporafenib和trametinib（MEKINIST）聯合用於具有RAS Q61X突變的局部晚期不可切除或轉移固體腫瘤惡性腫瘤患者的初步SEACRAFt-1 1期數據的口頭報告。會議將於10月23日至25日在西班牙巴塞羅那舉行。Naporafenib是一種潛在的首創和最佳的全RAF抑制劑。
Erasca plans to host a virtual investor event to provide a research and development (R&D) update on naporafenib and the RAS targeting franchise on Thursday, October 24, 2024, at 8:30 AM ET in conjunction with the 36th ENA Symposium. A live question and answer session will follow the formal presentation. To register for the event, please click here.
Erasca計劃舉辦虛擬投資者活動，就naporafenib和RAS靶向特許權進行研究與開發更新，在與第36屆ENA研討會同時於2024年10月24日星期四美國東部時間上午8:30舉行。正式演示之後將進行現場問答環節。要註冊參加此活動，請單擊此處。
譯文內容由第三人軟體翻譯。